Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Expansion Study to Evaluate the Safety and Efficacy of NSR-RPGR in Patients with a Diagnosis of X-linked Retinitis Pigmentosa (XLRP) due to RPGR mutations

Trial Profile

A Phase II/III Expansion Study to Evaluate the Safety and Efficacy of NSR-RPGR in Patients with a Diagnosis of X-linked Retinitis Pigmentosa (XLRP) due to RPGR mutations

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 07 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AAV-RPGR gene therapy-NightstaRx (Primary)
  • Indications Retinitis pigmentosa
  • Focus Registrational; Therapeutic Use
  • Sponsors Biogen; Nightstar Therapeutics
  • Most Recent Events

    • 07 Jun 2019 According to a Biogen media release, the company has acquired Nightstar Therapeutics.
    • 28 Nov 2018 New trial record
    • 13 Nov 2018 According to a Nightstar Therapeutics media release, this modified phase 2/3 expansion study is designed to be consistent with recommendations in FDAs draft guidance on the development of gene therapy products for retinal disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top